Assess pregnancy-related itch using bile acids and competing diagnoses, then individualise symptom relief, surveillance and birth timing according to fetal risk.
Intrahepatic cholestasis of pregnancy is a reversible pregnancy-associated disturbance of bile handling. The usual presentation is itch without a primary rash, sometimes worse at night and on the hands or feet, although symptoms may be generalised. Scratch marks are secondary damage and do not exclude cholestasis. The diagnostic task combines symptoms, raised total bile acids and exclusion of competing explanations; an elevated alanine aminotransferase alone does not quantify fetal risk. A normal initial blood result cannot end the assessment when the itch continues, because biochemical change may lag behind symptoms.
Risk communication should distinguish maternal discomfort from fetal risk. Severe itch can profoundly affect sleep without implying severe biochemical disease, while substantial bile acid elevation may occur in someone whose symptoms seem manageable. Ask about prior cholestasis, family history, gallstones, other liver disease, new medicines, dark urine, pale stools and systemic symptoms. Examine the skin for eczema, urticaria, infestation or pregnancy dermatoses and record blood pressure. Investigate unusually early, severe or persistent presentations more broadly, often with hepatology support.
Pregnancy hormones interact with inherited variation in hepatobiliary transport, helping explain familial clustering, recurrence and the usual improvement after delivery.
Previous cholestasis, multiple pregnancy and pre-existing hepatobiliary disease increase diagnostic suspicion, but many affected patients have no recognised prior hepatic disorder.
Reduced hepatobiliary handling allows bile acids to accumulate in maternal blood, while symptoms may precede measurable laboratory abnormality by days or weeks.
Raised maternal bile acids alter the fetoplacental environment; fetal complications become particularly important at high peak concentrations rather than in proportion to maternal itch.
Removal of pregnancy-related hormonal influence usually allows transport and biochemistry to recover, so persistence after the puerperium argues for a further hepatic explanation.
Palmar or plantar itching and nocturnal sleep disturbance are characteristic, but distribution alone neither confirms the diagnosis nor establishes biochemical severity.
Excoriations from scratching may be prominent; distinguish them from a primary inflammatory eruption that points towards dermatological disease.
Hypertension, diabetes or multiple pregnancy changes the assessment of fetal risk and may lead to a different birth plan from isolated singleton cholestasis.
Eczema, urticaria, scabies and pregnancy-specific dermatoses generally have identifiable skin findings, although coexistence with biochemical cholestasis remains possible.
Gallstone obstruction, viral hepatitis, autoimmune disease and medicine-induced injury can produce abnormal liver tests and itch; associated symptoms and targeted testing guide distinction.
Vomiting, severe pain, hypertension, haemolysis, thrombocytopenia, hypoglycaemia or coagulopathy suggest a systemic pregnancy emergency rather than isolated itchy cholestasis.
Pain, fever, marked jaundice, hepatomegaly or constitutional illness requires investigation for infection, obstruction, drug injury or pregnancy liver failure.
Both spontaneous labour and planned early delivery contribute to prematurity, making neonatal implications part of counselling when a severe biochemical result changes birth timing.
Meconium passage and stillbirth risk matter particularly in severe disease; other pregnancy complications further alter risk beyond the bile acid concentration alone.
Sleep loss and excoriation can be substantial, while fat-soluble vitamin malabsorption and impaired clotting occur less often and require targeted assessment when suspected.
Itch intensity correlates poorly with fetal risk, so a comfortable patient can still need a prompt change to the birth plan.
Routine ultrasound or CTG cannot reliably predict every ICP-related adverse event; reassurance must be tied to the present assessment rather than the remainder of pregnancy.
Recurrence is possible, so arrange baseline liver tests and bile acids early in a subsequent pregnancy and recheck promptly when symptoms recur.
Contraceptive choice is generally unrestricted after biochemical normalisation, but new itch during an estrogen-containing preparation warrants assessment rather than automatic attribution to pregnancy history.
Diagnosing cholestasis from itch alone and forgetting to reconsider a primary skin disorder or obstructed biliary system.
Using ALT magnitude or symptom intensity instead of bile acids to assign RCOG fetal-risk categories.
Allowing symptom improvement on ursodeoxycholic acid to cancel a previously justified discussion of planned birth.
Omitting postnatal blood tests because delivery has occurred and the patient reports some improvement.
Your practice draft is saved in this browser.
A patient with an otherwise uncomplicated singleton pregnancy has a peak bile acid concentration of 72 micromol/L at 35 weeks. Which planned birth range best matches RCOG advice?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
The obstetric plan uses peak bile acids and modifies it for multiple pregnancy, diabetes, pre-eclampsia and other concerns. In an otherwise uncomplicated singleton pregnancy, RCOG allows consideration of birth by 40 weeks for mild disease, recommends discussion of 38–39 weeks for moderate disease and 35–36 weeks for severe disease. These are counselling ranges, not an automatic instruction for caesarean birth. Explain the reason for the proposed timing, how new blood results can change it, and the limits of fetal monitoring in predicting a sudden adverse event.
Do not present the PITCHES regimen as a licensed ICP dose or claim it prevents stillbirth; review diarrhoea, interactions and the specific product information.
Keep emollient-contaminated clothing and bedding away from flames; worsening itch still requires the planned clinical and biochemical reassessment.